
a head and neck oncology podcast with Ben O’Leary and Will Ince (@will_oncology)
Boston, MA
Joined July 2025
- Tweets26
- Following29
- Followers48
- Likes6
deep margin retweeted
The identification of the tubarial gland is a really cool story, though I am doubtful that TG-sparing radiotherapy will make a meaningful difference to patient-reported xerostomia.
Sparing the contralateral TG should already effectively be part of standard practice for ipsilateral-only nodal disease, and the ipsilateral TG will receive dose from elective treatment of the RP nodes.
We recently looked at patient-reported outcomes as a function of tubarial gland dose and could not find a significant relationship (and this included patients treated without ENI, so there was a truly variable dose to the TG):
sciencedirect.com/science/ar…
A new organ has been found behind your nose.
For centuries, every anatomy textbook swore there were only three pairs of major salivary glands. Turns out the books were wrong, and the missing ones were hiding in plain sight.
In 2020, Dutch researchers scanning head-and-neck cancer patients with a cutting-edge PET/CT technique (PSMA PET-CT) noticed an unexpected glow deep in the nasopharynx, right where the nasal cavity drains into the throat. No textbook had ever marked a salivary gland there.
They double-checked: 100 consecutive patients → same structure in every single one. Then they dissected two fresh cadavers and there they were: a previously unknown pair of macroscopic salivary glands, roughly 3.9 cm long, draped over the tubarium (the cartilage of the Eustachian tube). The team named them the tubarial glands.
Their job? Keep the upper throat and the back of the nose moist during talking, swallowing, and breathing, an area that gets painfully dry after radiation.
Here’s why this matters: radiation oncologists had never been told to spare this spot. The researchers re-analyzed treatment plans from 723 patients and found the more radiation the tubarial region received, the worse the toxicity, more trouble swallowing, thicker saliva, constant dry mouth.
A simple anatomical blind spot had been quietly worsening outcomes for years.
Now that we know these glands exist, new radiation protocols can shield them, giving thousands of head-and-neck cancer patients an easier road to recovery.
[Valstar, de Bakker, et al., “Discovery of the tubarial salivary glands: a new organ at risk in radiotherapy for head and neck cancer,” Radiotherapy and Oncology 2021, DOI: 10.1016/j.radonc.2020.09.034]
deep margin retweeted
Pleased as punch to be invited onto the Deep Margin podcast, now a fixture in HN calendar.
Privilege to follow @DavidSherMD @DrUppaluri
Great fun chatting salvage surgery with @nearlobey @will_oncology Serious topic, yet an easy listen. Do tune in tinyurl.com/57s3jynv
deep margin retweeted
I don't think I've ever had this much fun talking about radiotherapy.
We discussed ENI, immunotherapy (and radiotherapy) in metastatic and non-metastatic HNSCC, oligometastatic disease, to name a few.
New episode alert with the wonderful @DavidSherMD who talks us through the immunotherapy radiation paradigm….
open.spotify.com/episode/11H…
deep margin retweeted
#ESMOAsia25
🚨JUPITER-02 Final 6-year OS analysis presented!
1L toripalimab + gem/cis in pts with RM-Nasopharyngeal Ca
Median OS 64.8 vs 33.7 mo
(HR 0.62; p<0.01)
Adjusted post-prog IO: 61.0 vs 25.1 mo (HR O.52)
Confirms long-term toriGP combo efficacy
👇Updated situation of 1L NPC
@OncoAlert @brunolarvol #oncoalertAF
#NPC #Immunotherapy
Still work to do by western regulatory agencies to ensure access to immuno-chemo combos for patients with R/M nasopharyngeal carcinoma
Players⛹🏾♂️⛹🏽♀️
toripalimab, tislelizumab, penpulimab, camrelizumab
@brunolarvol @BAHNOOfficial @OracleHNCUK @OncoAlert @ttccgroup
Among others
🇬🇧 UK (NICE) Tori/ Tisle Pending
🇨🇦 Canada (AMC) Tori/ Tisle Pending
🇪🇺 European Union (EMA) Tori/Tisle Approved for use, but reimbursement pending in many countries
deep margin retweeted
Had a lot of fun discussing perioperative trials in LA-HNSCC with @deepmargin_pod @will_oncology BenO'Leary !!! KEYNOTE-689, NIVOPOSTOP and future directions! @DrHaddadRobert @imrtlee @HeadNeckMD
open.spotify.com/episode/5s0… At end we discuss @jvuppaluri favorite @premierleague team!
deep margin retweeted
"A Simplified Guide to the Immune System."
pin.it/1Krc811Dg
deep margin retweeted
#ESMO25 @myESMO Abstracts are now released!
Here is my summary with preliminary results from the best communications for:
🔸Head&Neck SCC
- Early disease - Advanced disease
🔸Nasopharyngeal Carcinoma
🔸SalivaryGlandCancer & Sinonasal
@oncodaily @OncoAlert @brunolarvol @OncBrothers @FundacionTTCC
#headneckcancer #ESMO2025
deep margin retweeted
One week to #ESMO25. An unprecedented ESMO conference. Seven positive press releases, anticipating the expansion of T-DXd to the curative setting, two Trop2 ADCs reaching first-line mTNBC, 2 novel ET-based combos, adjuvant CDK4/6i improving OS. See you in Berlin! #ESMOAmbassadors
deep margin retweeted
FDA approves adjuvant cemiplimab for high risk cutaneous SCC based on C-POST phase III trial presented at #ASCO2025 #skincancer @OncoAlert @brunolarvol @myESMO #CSCC
350mgQ3Wx4cycles followed by 700mgQ6Wx6cycles
High-risk disease criteria:
🔸Nodal: ECE + ≥1 node ≥20 mm or ≥3 involved nodes.
🔸 Non-nodal: in-transit mets, p/n of named nerves, T4 bone invasion, or local recurrence with extra adverse features (e.g. ≥N2b, T3 > 4 cm, or poor differentiation ≥ 20 mm)
deep margin retweeted
2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi for their discoveries concerning peripheral immune tolerance
A stunningly preserved evolutionary regulation that erases or controls self-reactive T cells
deep margin retweeted
🚨Update in Head&Neck SCC @NCCN Evidence Blocks
💉neoadjuvant #pembrolizumab added!
Highlighting indication for resectable stage III/IVa CPS+, excluding N3
💉Sc R/M #nivolumab (review new doses 600mgQ2W/1200mgQ4W)
👇v5 Pics @OncoAlert @brunolarvol @BAHNOOfficial @ttccgroup


































